A single drop of blood may soon hold the key to detecting the earliest stages of dementia. Recent research suggests it’s not how much of a protein is present, but whether it maintains its normal shape that truly matters.
The Shift from Quantity to Quality in Biomarker Research
Researchers at the Scripps Research Institute analyzed blood samples from 520 individuals – including those with normal cognitive function, mild cognitive impairment (MCI), and Alzheimer’s disease – and found they could distinguish between normal cognition and MCI with approximately 93% accuracy by assessing the state of three specific proteins.
The study included 227 healthy individuals, 135 with MCI, and 158 diagnosed with Alzheimer’s disease.
MCI represents a transitional stage where cognitive abilities begin to decline, but daily life remains largely unaffected. It’s a critical period as it can precede the development of Alzheimer’s disease.
Beyond Amyloid and Tau: A New Approach
Current blood tests for dementia primarily measure the levels of amyloid and tau proteins, which are known to accumulate in the brain and damage nerve cells. Higher concentrations are typically associated with an increased risk of Alzheimer’s.
This new research takes a different tack. Instead of quantifying protein levels, it focuses on whether these proteins are properly folded and maintaining their functional structure.
Proteins must fold into specific shapes to perform their roles. Disease progression can disrupt this folding process. The research team used markers to identify the state of the proteins, with more markers attaching to those with disrupted structures. This allowed for a numerical analysis of protein stability.
The analysis revealed that protein states became increasingly unstable as the disease progressed, with a clear pattern emerging from normal cognition to MCI to Alzheimer’s.
Importantly, protein state changes were detected in 42% of the samples, compared to only 32% based on protein quantity differences, indicating a greater ability to discern subtle changes.
The Protein Trio: C1QA, Klusterin, and ApoB
The research team identified three proteins – C1QA (involved in immune response), Klusterin (involved in clearing damaged proteins), and ApoB (involved in transporting lipids in the blood) – and analyzed changes in their states collectively.
The accuracy of distinguishing between normal cognition and MCI was approximately 93%, meaning the test correctly identified 93 out of 100 individuals.
This approach differs from existing research that focuses on measuring the quantity of proteins in the blood to predict dementia risk.
Researchers believe these changes may reflect early signals not detectable through conventional testing.
Future Directions and Challenges
Although promising, this method isn’t ready for widespread clinical use. The study size is limited, the follow-up period is relatively short, and the analysis process is complex, requiring further validation.
The significance of this research lies in expanding the criteria for assessing dementia – shifting the focus from protein quantity to protein state. The state of a protein, rather than simply its abundance, may serve as an early indicator of disease.
The findings were published in the journal Nature Aging on February 27, 2026.
Frequently Asked Questions
Q1. Can blood tests currently predict dementia?
A1. Not yet. It’s still in the research phase. Widespread use requires confirmation in larger studies and long-term validation.
Q2. Is this test better than existing ones?
A2. Existing tests already demonstrate high accuracy. This research presents a different approach – focusing on protein state rather than quantity.
Q3. Who would benefit most from this research?
A3. Individuals seeking to identify changes before symptoms appear, or in the early stages of the disease. Earlier detection could allow for timely intervention.
Q4. What’s needed to make this a standard clinical test?
A4. Replication of the results in larger studies and simplification of the testing process for use in hospitals are necessary.
